ライフサイエンスコーパス: BMP-2

1 exed with conventional plasmid DNA (encoding BMP-2).

2 expression of bone morphogenetic protein 2 (BMP-2).

3 tration-approved bone morphogenic protein 2 (BMP-2).

4 al in treated animals that was equivalent to BMP-2.

5 pendent transcription of CSF-1, osterix, and BMP-2.

6 ls display directed migration in response to BMP-2.

7 of multinucleated osteoclasts in response to BMP-2.

8 lates phosphorylation of Smad in response to BMP-2.

9 of GATA-6, and this is reversed by exogenous BMP-2.

10 9 in the manner that Alk3 is positioned onto BMP-2.

11 in calcifying vascular cells, as mediated by BMP-2.

12 a phenomenon that could be fully rescued by BMP-2.

13 and mimicked by stimulation with recombinant BMP-2.

14 y for motility in response to S100A4/Mts1 or BMP-2.

15 interaction and the interaction of HJV with BMP-2.

16 ity of the clinically licensed growth factor BMP-2.

17 action only between the collagen IIa vWC and BMP-2.

18 e 1 (ALK1) and ALK5 downstream TGF-beta1 and BMP-2.

19 ation marker of odontoblasts is regulated by BMP-2.

20 ralisation beyond the current gold-standard, BMP-2.

21 and BMP-7, but not the frog Cerberus ligand BMP-2.

22 tro by periosteal cells treated with Ihh and BMP-2.

23 METHODS AND Both S100A4/Mts1 (500 ng/mL) and BMP-2 (10 ng/mL) induce migration of hPASMCs in a novel

24 ked in saline, bone morphogenetic protein-2 (BMP-2; 200 ng), 1 muM CGS21680 (A2AR agonist, EC50 = 160

25 a-binding proteins and between prodomains of BMP-2, -4, -7, and -10 and GDF-5 and fibrillins, raising

26 affinity docking site for the propeptides of BMP-2, -4, -7, and -10 and GDF-5, but not GDF-8, and loc

27 e I receptor Alk1, but not other Alks, while BMP-2, -4, and -7 bind and signal through Alk3, and the

28 BMP-2, -4, and Runx2 expression was observed after 3 day

29 The cellular response to the Drosophila BMP 2/4-like ligand Decapentaplegic (DPP) serves as one

30 Signaling by both BMP-2/4 and BMP-6/7 was mediated by homodimers of ACVR1A

31 r utilization differed significantly between BMP-2/4 and BMP-6/7.

32 PD-L2 and BMP-2/4 bind to distinct sites on RGMb.

33 A greater reliance on BMPR2 was observed for BMP-2/4 relative to BMP-6/7, whereas ACVR2A was more cri

34 MPR1A and ACVR1A expression, suggesting that BMP-2/4 signal in part through ACVR1A/BMPR1A heterodimer

35 A portion of BMP-2/4 signaling also required concurrent BMPR1A and AC

36 Although BMP-2/4 used predominantly BMPR1A for signaling, ACVR1A

37 ese results suggest different mechanisms for BMP-2/4- and BMP-6/7-induced osteoblastic differentiatio

38 main of TSP-1 is likely responsible for this BMP-2/4-binding activity, an assertion based on sequence

39 s more critical to signaling by BMP-6/7 than BMP-2/4.

40 we identified for the first time TSP-1 as a BMP-2/-4 antagonist and presented a structural basis for

41 nsights into the involvement of TSP-1 in the BMP-2/-4 mechanisms of action.

42 rkedly enhanced bone regeneration as well as BMP-2 8 wk after surgery (60 +/- 2%, 79 +/- 2%, and 75 +

43 ECFCs produced bone morphogenetic protein-2 (BMP-2), a potent osteoinductive molecule, and increases

44 ffold alone and as much bone regeneration as BMP-2, a growth factor currently used to promote bone re

45 cocultures that were stimulated with EMD and BMP-2 achieved significantly higher levels of these fact

46 rats, it was shown that PEI-cmRNA (encoding BMP-2)-activated matrices promoted significantly enhance

47 ne regeneration compared to PEI-plasmid DNA (BMP-2)-activated matrices.

48 we found a novel signaling pathway in which BMP-2 activates Dspp gene transcription via Dlx3/Osx pat

49 nation of cytoskeletal changes and increased BMP-2 activity.

50 s containing lyophilized adenovirus encoding BMP-2 (AdBMP-2) or freely suspended AdBMP-2 were transpl

51 ntiation using bone morphogenetic protein 2 (BMP-2) added to the medium.

52 vested from C57/BL6 mice, transfected with a BMP-2 adenovirus, seeded on collagen scaffolds (ossicles

53 However, in vitro studies demonstrate that BMP-2 alone does not influence blastema cell migration,

54 BMPR1A and ligation of the BMP receptor with BMP-2 also activated GTP-Rho A of these SMCs, while DN B

55 3-kinase/Akt signaling acting downstream of BMP-2 also drives NFATc1 expression and transcriptional

56 firmed that recombinant human TSP-1 can bind BMP-2 and -4 and antagonize their effects on C3H10T1/2 c

57 um contains a factor that inhibits action of BMP-2 and -4.

58 Both BMP-2 and a PPARgamma agonist stimulated production and

59 In conclusion, Nov binds BMP-2 and antagonizes BMP-2 and Wnt activity, and its ov

60 nanodiamonds (NDs) as a delivery vehicle for BMP-2 and basic fibroblast growth factor (bFGF).

61 We find that both BMP-2 and bFGF are readily loaded onto NDs by physisorpt

62 Simultaneous delivery of BMP-2 and bFGF by ND induces differentiation and prolife

63 e injectable alternative for the delivery of BMP-2 and bFGF to promote bone formation.

64 urvival by regulating endoderm expression of BMP-2 and BM during embryonic epithelial morphogenesis.

65 pattern, we examined the functional roles of BMP-2 and BMP signaling in post-EMT valvulogenesis by us

66 These data provide evidence that BMP-2 and BMP signaling induce biological processes invo

67 , and HJV enhances utilization of ActRIIA by BMP-2 and BMP-4.

68 Increased glucose augmented expression of BMP-2 and BMP-4; the BMP inhibitors matrix Gla protein (

69 K cells express type I and II BMP receptors, BMP-2 and BMP-6 ligands, and phosphorylated isoforms of

70 osphorylation of Smad1/5, mRNA synthesis for BMP-2 and BMP-6, and cell growth in MCF10AT1 cells.

71 known high affinity ActRIIB ligand, whereas BMP-2 and BMP-7 affinities for ActRIIB are at least 100-

72 ne residue at the corresponding positions of BMP-2 and BMP-7 allowed for molecular engineering of rec

73 Oligodendrocytes expressed BMP-2 and BMP-7 and pSMAD1/5/8.

74 Expression levels of BMP-2 and BSP were significantly upregulated by OIM and

75 ity of these vWC domains to directly bind to BMP-2 and detected an interaction only between the colla

76 In this report, we investigated if BMP-2 and FGF-2 together can synergistically promote bon

77 onstructs - (1) Lv-BMP/GFP, containing human BMP-2 and green fluorescent protein (GFP) gene (BMP grou

78 Indeed, TNF-alpha could induce BMP-2 and its receptor (BMPR1A) in human skin and primar

79 Thus, the proteolysis and activation of pro-BMP-2 and mature BMP-2 by FSAP can regulate cell differe

80 Our finding that BMP-2 and neogenin bind simultaneously to hemojuvelin ra

81 To analyze a functional link between BMP-2 and NFATc1, we analyzed bones from OB-specific BMP

82 MMP-1 and -8, RANK, and RANKL and increased BMP-2 and OPG levels in the periodontal tissue.

83 (ox-PAPC) on osteogenic signaling induced by BMP-2 and PTH in MC3T3-E1 cells.

84 pids inhibit osteogenic signaling induced by BMP-2 and PTH, raising the possibility that hyperlipidem

85 els stimulates new bone formation as well as BMP-2 and represents a novel approach to stimulating bon

86 Similarly, vascular BMP-2 and RUNX2 were upregulated in atherosclerotic mice

87 allowed us to conclude that all, except for BMP-2 and the short BMP-4 propeptides, formed complexes

88 Various doses of LIF and BMP-2 and their inhibitors or blocking antibodies were t

89 conclusion, Nov binds BMP-2 and antagonizes BMP-2 and Wnt activity, and its overexpression inhibits

90 d sustained by bone morphogenetic protein-2 (BMP-2) and TGF-beta, respectively.

91 expression of bone morphogenetic protein 2 (BMP-2) and the transcription factor RUNX2, which normall

92 rowth factors, bone morphogenetic protein 2 (BMP-2) and vascular endothelial growth factor (VEGF).

93 1 (TGFbeta-1), bone morphogenetic protein-2 (BMP-2), and BMP-6 were measured by real-time RT-PCR, and

94 d increased mRNA levels of FGF-2, TGFbeta-1, BMP-2, and BMP-6.

95 BMP-4, BMP-2, and BMP-7 inhibited basal and tumor necrosis fact

96 lume, expression of osteogenic genes (RUNX2, BMP-2, and ColI), bone formation rate (BFR), and mineral

97 of BMSCs of wild-type and Bag-1(+/-) mice to BMP-2, and promoted robust BMP-2-stimulated osteogenic d

98 Tgfbeta1, -2, and -3 (but not BMP-2, another member of the Tgfbeta superfamily) induce

99 Cotreatment with the BMP-2 antagonist DMH1 limits, but does not block, parben

100 ctor runx2, neither warfarin, BMP-2, nor the BMP-2 antagonist noggin altered runx2 mRNA content in ao

101 The addition of Noggin, a BMP-2 antagonist, neutralized the stimulatory effects of

102 In addition, TGF-beta1 and BMP-2 antagonized tumor necrosis factor alpha-induced IL

103 ical PC cleavage site, giving rise to mature BMP-2 (Arg(282) downward arrowGln(283)), as well as in t

104 This work identifies TGF-beta1 and BMP-2 as potent inhibitors of IL-34 expression in RA syn

105 P enhances the biological activity of mature BMP-2 as well as its pro-form, as shown by osteogenic di

106 ding proinflammatory TGFbeta1 and osteogenic BMP-2, as well as glycosaminoglycans such as heparan sul

107 , we identified the requirements of c-Abl in BMP-2 autoregulation and the expressions of alkaline pho

108 h in turn would influence the amount of free BMP-2 available for binding to its receptors and trigger

109 y activation and expression of TGF-beta1 and BMP-2 between healthy and diseased tendon tissues and ce

110 Hence, as a novel BMP-2-binding protein and antagonist in the cartilage ex

111 y from that in CV-2 vWC, which comprises its BMP-2-binding site.

112 It is reported that BMP-2 binds to BMPR1A, another BMP type 1 receptor, wher

113 n of these results with complex formation by BMP-2, BMP-4 (full-length and shortened propeptides), BM

114 In the present study, we show that BMP-2, BMP-4, and BMP-6 are endogenous ligands for HJV i

115 sis (MS), we characterized the expression of BMP-2, BMP-4, BMP-5, and BMP-7; BMP type II receptor (BM

116 microglia/macrophages, and neurons expressed BMP-2, BMP-4, BMP-5, and BMP-7; BMPRII; and pSMAD1/5/8.

117 The expression of BMP-2, BMP-4, BMP-5, BMP-7, BMPRII, and pSMAD1/5/8 was q

118 tudy was to evaluate receptor utilization by BMP-2, BMP-4, BMP-6, and BMP-7 in primary human mesenchy

119 iple members of the BMP subfamily, including BMP-2, BMP-4, BMP-7, and GDF-5, with similar kinetics an

120 We also measured the effects of BMP-2, BMP-4, BMP-7, and the BMP inhibitor LDN-193189 on

121 onal NMR and functional activity assays with BMP-2, BMP-7 and GDF-5 as ligands.

122 ibited signaling by the low affinity ligands BMP-2, BMP-7, and BMP-9.

123 BMP-2/BMP-RII signaling prevented PDGF-BB-induced prolif

124 ctively, whereas only one of six mice of the BMP-2/BMSC combination showed evidence of metastatic spr

125 compared with BMP-2-coupled, BMSC-seeded, or BMP-2/BMSC-combined treatment.

126 In osteoblasts, CypA is necessary for BMP-2 (Bone Morphogenetic Protein-2)-induced Smad phosph

127 ariants with the corresponding residues from BMP-2 bound BG(ZP-C) more weakly than corresponding alan

128 n of the periostin promoter, were induced by BMP-2 but repressed by noggin in cushion mesenchymal cel

129 lysis and activation of pro-BMP-2 and mature BMP-2 by FSAP can regulate cell differentiation and calc

130 e explored the physiological presentation of BMP-2 by using a biomaterial that harbors tunable mechan

131 enesis, there is evidence that high doses of BMP-2 can lead to side effects, including inflammation a

132 ins of two proteins thought to interact with BMP-2: collagen IIA and matricellular protein CCN3.

133 crog (optimal) or 0.1 microg (suboptimal) of BMP-2 combined with 0, 2, 4, or 8 microg of GST-BGN.

134 fect were formed in the groups of suboptimal BMP-2 combined with 4 or 8 microg of GST-BGN.

135 modified ribonucleic acid (cmRNA) (encoding BMP-2) complexed with polyethylenimine (PEI) and made co

136 ctionalized to the microcarriers surface for BMP-2 conjugation.

137 adigm in which bone morphogenetic protein 2 (BMP-2) consecutively and interdependently activates the

138 Untreated scaffolds were compared with BMP-2-coupled, BMSC-seeded, or BMP-2/BMSC-combined treat

139 TGF-beta1 and BMP-2 decreased IL-34 expression in the synovial fibrobl

140 uronic acid (HA)-based hydrogel was used for BMP-2 delivery to evaluate the influence of hydrogel deg

141 ER by HSC70, in modulation of E2-facilitated BMP-2-directed osteoblast development.

142 P-2, while genes with roles in inhibition of BMP-2-directed osteoblastogenesis were significantly upr

143 nificant downregulation of E2/ER-facilitated BMP-2-directed osteogenic differentiation of BMSCs.

144 present study, bone morphogenetic protein-2/BMP-2-directed osteogenic differentiation of bone marrow

145 pression profiling and identified miR-322, a BMP-2-down-regulated miRNA, as a regulator of osteoblast

146 t-transcriptional silencing of TFII-I during BMP-2-driven osteoblast differentiation in the C2C12 cel

147 MGP inhibits calcification independent of BMP-2-driven osteogenesis and only in the absence of pyr

148 The GH carrier containing OP3-4 with BMP-2 enlarged the radio-opaque area and increased the b

149 Silencing TLR2 and TLR4 in AVICs reduced BMP-2 expression and ALP activity to PVIC levels.

150 nd that this may be due in part to increased BMP-2 expression in medial SMCs.

151 ing that we have previously shown to enhance BMP-2 expression in osteoblasts.

152 In conclusion, oxLDL induces BMP-2 expression through TLR2 and TLR4 in human CAECs.

153 BMP-2 expression was associated with activation of nucle

154 The roles of TLR2 and TLR4 in oxLDL-induced BMP-2 expression were determined by pretreatment with ne

155 Inhibition of NF-kappaB and ERK1/2 reduced BMP-2 expression whereas inhibition of p38 MAPK had no e

156 influence cell proliferation, down-regulated BMP-2 expression, and showed no effect on BMP receptor t

157 e receptor (TLR) 2 and TLR4 in oxLDL-induced BMP-2 expression, and the signaling pathways involved.

158 of these two receptors reduced oxLDL-induced BMP-2 expression.

159 luteolin significantly increased TIMP-1 and BMP-2 expressions and decreased MMP-8 levels.

160 Like osteoblast cell numbers, BMP-2 expressions were also elevated in luteolin groups.

161 irate concentrate (BMAC) and growth factors (BMP-2, FGF-2, and FGF-8) and 2) increase matrix strength

162 This indicated a requirement of BMP-2 for NFATc1 expression in OBs.

163 cking any posttranslational modifications on BMP-2 function in vitro and in vivo.

164 derived BGN on bone morphogenetic protein 2 (BMP-2) function, which is exerted likely via the BGN cor

165 inhibition of microtubule assembly enhances BMP-2 gene transcription and subsequent bone formation,

166 e up-regulates bone morphogenetic protein 2 (BMP-2) gene expression and activity.

167 N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(

168 ombinant human-like collagen (HLC) and human BMP-2 (hBMP2).

169 d that upon treatment with recombinant human BMP 2 in high-density micromass culture, mutant disc cel

170 MATN3 bound BMP-2 in a dose-dependent manner.

171 ry, and provascularized characteristics over BMP-2 in bone tissue engineering, is highlighted, which

172 tional interaction between NF-kappaB p65 and BMP-2 in chondrocytes.

173 ls containing significantly reduced doses of BMP-2 in combination with physiologically relevant doses

174 ese data show a role of NFATc1 downstream of BMP-2 in mouse bone development and provide novel eviden

175 known to be critical for AV EMT, the role of BMP-2 in post-EMT AV valvulogenesis remains to be elucid

176 We show that BMP-2, in a phospho-Akt-dependent manner, induces betaC

177 Interestingly, BMP-2 induced calcium release from intracellular stores

178 rkC suppresses bone morphogenetic protein 2 (BMP-2)-induced Smad1 phosphorylation and transcriptional

179 Actually, OP3-4 enhanced the BMP-2-induced 5-bromo-2'-deoxyuridine (BrdU)-positive ce

180 her OP3-4, a RANKL-binding peptide, promotes BMP-2-induced bone formation in the murine maxilla using

181 of OP3-4 by subperiosteal injection promoted BMP-2-induced bone formation, which could lead to the de

182 The effects of c-Abl on BMP-2-induced bone remodeling and the underlying mechani

183 ase inhibitor GW4869, significantly enhanced BMP-2-induced differentiation and maturation of chondroc

184 During BMP-2-induced differentiation of preosteoblasts, decreas

185 ure, GW4869 treatment significantly promoted BMP-2-induced hypertrophic maturation and calcification

186 sitol 3-kinase/Akt, and Ca(2+) signaling for BMP-2-induced NFATc1 expression through an autoregulator

187 bits calcineurin upstream of NFATc1, blocked BMP-2-induced NFATc1 mRNA and protein expression.

188 Interestingly, c-Abl regulated BMP-2-induced osteoclastogenic CSF-1 expression.

189 PI 3-kinase and canonical Smads to integrate BMP-2-induced osteogenesis.

190 In the C2C12 cell culture system, BMP-2-induced Smad 1/5/8 phosphorylation and alkaline ph

191 alphavbeta3 integrin is required to mediate BMP-2-induced Smad signaling through a Cdc42-Src-FAK-ILK

192 of intracellular calcium abundance, blocked BMP-2-induced transcription of NFATc1.

193 BMP-2 induction leads to the expression of inhibitory Sm

194 opposite of miR-199a(*) expression following BMP-2 induction.

195 he mutation of the heparin binding region of BMP-2 inhibited the processing by FSAP but not by PC.

196 this effect was abrogated by a physiological BMP-2 inhibitor, noggin.

197 Bone morphogenetic protein 2 (BMP-2) initiates receptor-regulated Smad phosphorylation

198 The local bone formation in the OP3-4-BMP-2-injected group was analyzed in comparison to the c

199 njected, BMP-2-injected, and control-peptide-BMP-2-injected groups.

200 lyzed in comparison to the carrier-injected, BMP-2-injected, and control-peptide-BMP-2-injected group

201 BMP-2 is highly expressed in the majority of non-small c

202 BMP-2 is produced as a large pro-form and secreted as a

203 We show that matrix-bound BMP-2 is sufficient to induce beta3 integrin-dependent C

204 Bone morphogenetic protein 2 (BMP-2) is essential for postnatal bone formation and fra

205 Although bone morphogenetic protein 2 (BMP-2) is known to stimulate osteogenesis, there is evid

206 hypertension (PAH); the ligand for BMP-RII, BMP-2, is a negative regulator of SMC growth.

207 d NFATc1, we analyzed bones from OB-specific BMP-2 knock-out mice for NFATc1 expression by immunohist

208 itol 3-kinase (PI 3-kinase)/Akt signaling by BMP-2 leads to osteoblast differentiation.

209 fied arteries, bone morphogenetic protein 2 (BMP-2)levels were increased at the time of injury sugges

210 Treatment of the mutant EBs with BMP-2 markedly suppresses apoptosis, whereas stable over

211 TGF-beta and BMP-2 may be important modulators of vitreous-induced ch

212 and noncanonical Wnt pathways is required in BMP-2-mediated angiogenesis.

213 1/2) as specific signaling components of LIF+BMP-2-mediated CMC differentiation.

214 ecific inhibitors drastically suppressed LIF+BMP-2-mediated CMC differentiation.

215 tic knockout of Akt2, did not interfere with BMP-2-mediated signaling but resulted in inhibition of o

216 in response to injury, factors that subvert BMP-2-mediated tandem activation of Wnt-betaC and Wnt-PC

217 thout activating RhoA-Rac1 not only prevents BMP-2-mediated vascular smooth muscle cell motility but

218 At the same time, BMP-2 mediates phosphorylated Smad1 (pSmad1) or, with lo

219 By screening chemical libraries for BMP-2 mimics using a cell-based assay, we identified inh

220 Unlike BMP-2, Nell-1 cannot initiate ectopic bone formation in

221 ranscription factor runx2, neither warfarin, BMP-2, nor the BMP-2 antagonist noggin altered runx2 mRN

222 ation, the synergistic effect of Nell-1 with BMP-2 on osteogenesis, as well as the advantages of Nell

223 of TGF-beta and bone morphogenic protein 2 (BMP-2) on epithelial gene expression.

224 calvarial defect model when transduced with BMP 2 or 4; however, the contribution of the donor cells

225 it tip regeneration, and that treatment with BMP-2 or -7 induces a regenerative response following am

226 ced pSMAD1/5/9 levels when induced either by BMP-2 or BMP-7, suggesting that ACVR1 is the major recep

227 Exogenous BMP-2 or caBMPR-1B (ALK6) treatments significantly promo

228 Exogenous BMP-2 or constitutively active (ca) BMPR-1B (ALK6)-virus

229 zed two kinds of plasmid DNA encoding either BMP-2 or FGF-2 formulated into polyethylenimine (PEI) co

230 Our studies demonstrate how a single ligand (BMP-2 or S100A4/Mts1) can recruit multiple cell surface

231 is regulated by numerous factors, including BMP-2, parathyroid hormone, and 1alpha,25-dihydroxyvitam

232 mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289) downward arrowLys(290)).

233 BMP-2 plays a significant role in bone generation and re

234 Bone morphogenetic protein-2 (BMP-2) plays an important role in atherosclerotic vascul

235 ozone group and the same group revealed more BMP-2 positivity compared with other groups.

236 e complex of crossveinless-2 (CV-2) vWC1 and BMP-2 previously revealed one mode of the vWC/BMP-bindin

237 kdown of FSAP in hepatocytes, which revealed BMP-2 processing by endogenous FSAP.

238 e of MSCs with ECFCs transduced to knockdown BMP-2 production abrogated the osteogenic response to le

239 atical model, where mechanical regulation of BMP-2 production mediates rates of cellular proliferatio

240 showed good activity in inducing osteoblast BMP-2 production.

241 IL-34, TGF-beta1, and BMP-2 productions were measured in patient synovial flui

242 oxidized low density lipoprotein (oxLDL) on BMP-2 protein expression in human coronary artery endoth

243 Stimulation with oxLDL increased cellular BMP-2 protein levels in a dose-dependent manner (40-160

244 very of active bone morphogenetic protein-2 (BMP-2) protein to responsive target cells, such as bone

245 gulates a multistep process to control first BMP-2 receptor activity and second the inhibitory role o

246 MMP-1 and -8), bone morphogenetic protein-2 (BMP-2), receptor activator of nuclear factor kappaB (RAN

247 We provide evidence that BMP-2 regulates Sdf-1alpha expression in endothelial cel

248 We hypothesized that BMP-2 regulation of Dspp transcription was mediated by D

249 Furthermore, BMP-2 release increased with either a decrease in the in

250 tly, two hydrogel formulations with distinct BMP-2 release profiles were evaluated in a critical-size

251 lls from BMP group showed >1,000-fold higher BMP-2 release, and the majority of them stained intensel

252 such side effects by reducing the amount of BMP-2 required to obtain a sufficient amount of bone.

253 er expression of TLR2 and TLR4 and a greater BMP-2 response than AVICs from normal valves.

254 tant role for TLR2 and TLR4 in mediating the BMP-2 response to oxLDL in human CAECs and indicate that

255 ssion of TLR2 and TLR4 enhanced the cellular BMP-2 response to oxLDL.

256 rate that overexpression of miR-322 enhances BMP-2 response, increasing the expression of Osx and oth

257 observed in the complex between CV-2 vWC and BMP-2, revealing an alternative mode of interaction betw

258 nt osteoinductive molecule, and increases in BMP-2 secretion correlated with gel stiffness.

259 e coupled with bone morphogenetic protein-2 (BMP-2), seeded with bone marrow stromal cells (BMSC), an

260 showed that inhibitory effects of ox-PAPC on BMP-2 signaling were associated with inhibition of SMAD

261 1, a well established downstream molecule of BMP-2 signaling, as a putative target of miR-199a(*).

262 ts transcriptional target apoE downstream of BMP-2 signaling.

263 e mechanical properties to promote localized BMP-2 signaling.

264 der calcifying conditions , stimulation with BMP-2 significantly increased cell proliferation, howeve

265 For hydrogels that contained BMP-2, similar volumes of new bone tissue were formed; h

266 ature chondrocyte hypertrophy by suppressing BMP-2/Smad1 activity.

267 for TbetaRIII function, we demonstrate that BMP-2 specifically stimulates TbetaRIII-mediated epithel

268 f-2, Fgf-18, and bone morphogenic protein 2 (Bmp-2)] still were present in Fgf-9(+/-) mice, they coul

269 In the present investigation, we found that BMP-2 stimulated expression and nuclear translocation of

270 downstream of bone morphogenetic protein-2 (BMP-2)-stimulated osteoblast-coded factors.

271 peptide, an inhibitor of NFATc1, suppressed BMP-2-stimulated NFATc1 transcription, confirming its au

272 BMP-2-stimulated osteoblast differentiation additionally

273 ag-1(+/-) mice to BMP-2, and promoted robust BMP-2-stimulated osteogenic differentiation of BMSCs.

274 inhibition of c-Abl significantly suppressed BMP-2-stimulated PI 3-kinase activity and its downstream

275 We examined the role of calcium in BMP-2-stimulated regulation of NFATc1 in osteoblasts.

276 pertrophic chondrocytes led to inhibition of Bmp-2-stimulated, BMP-responsive element-dependent Col X

277 new chemical entities (NCEs) that have shown BMP-2 stimulation and osteoblast differentiation are rep

278 pendent expression of Smpd3 was increased by BMP-2 stimulation.

279 l and MC3T3 osteoblastic cells increased the BMP-2 stimulatory effect on alkaline phosphatase activit

280 infection of AV endocardial cells abolished BMP-2-supported AV endocardial EMT.

281 way, since this pathway is known to regulate BMP-2 transcription in osteoblasts and microtubules have

282 rs of microtubule assembly as stimulators of BMP-2 transcription.

283 tenuated chondrogenesis in recombinant human BMP 2-treated mutant disc cultures.

284 in four of four mice bearing scaffolds with BMP-2 treatment and with BMSC treatment, respectively, w

285 n of common cardiogenic factors, Nkx-2.5 and Bmp-2, until HH Stage 10, when a tubular heart has forme

286 In this study, we report that BMP-2, via BMPRII-mediated inhibition of GSK3-beta, indu

287 We showed that BMP-2, via the receptor-specific Smad pathway, regulates

288 Similarly, mature BMP-2 was also cleaved to a truncated peptide within its

289 strated that the antiproliferative effect of BMP-2 was BMP-RII, PPARgamma, and apoE dependent.

290 N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage s

291 Binding of MATN3 with BMP-2 was determined by immunoprecipitation, solid phase

292 A GH carrier containing OP3-4 with BMP-2 was subperiosteally injected into the murine maxil

293 ded with simvastatin (pro or active drug) or BMP-2, we have demonstrated osteogenic differentiation w

294 dues, BG bound bone morphogenetic protein 2 (BMP-2) weakly or not at all, and TGF-beta2 variants with

295 IL-34, TGF-beta1, and BMP-2 were expressed in synovial fluids from RA patients

296 MAD1/5/9 (pSMAD1/5/9) levels when induced by BMP-2, whereas no impacts on pSMAD1/5/9 were observed wh

297 ltures of Bag-1(+/-) BMSCs supplemented with BMP-2, while genes with roles in inhibition of BMP-2-dir

298 ll interference RNA (siRNA) or antagonism of BMP-2 with noggin prevented matrix mineralization in vit

299 surface not only provided immobilization of BMP-2 with prolonged bioavailability, but also enhanced

300 -2 (FGF-2) and bone morphogenetic protein-2 (BMP-2) work synergistically to encourage osteogenesis in